Prosecution Insights
Last updated: November 04, 2026
Application No. 17/436,662

METHOD FOR SEPARATING CELLS USING A STIMULUS-RESPONSIVE POLYMER

Final Rejection §103§112
Filed
Sep 07, 2021
Priority
Mar 08, 2019 — DE 10 2019 106 011.7 +1 more
Examiner
PENNINGTON, KATIE LEIGH
Art Unit
1634
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Universität Siegen
OA Round
4 (Final)
32%
Grant Probability
At Risk
5-6
OA Rounds
0m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants only 32% of cases
32%
Career Allowance Rate
22 granted / 68 resolved
-27.6% vs TC avg
Strong +60% interview lift
Without
With
+60.2%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
49 currently pending
Career history
136
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
40.9%
+0.9% vs TC avg
§102
13.6%
-26.4% vs TC avg
§112
30.2%
-9.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 68 resolved cases

Office Action

§103 §112
DETAILED ACTION Applicant’s amendment and Arguments/Remarks received on 19 August 2026 have been entered. Claims 1-14 and 16-20 were previously pending in the application. No claims have been cancelled, and new claim 21 has been added by Applicant. Claims 1-14 and 16-21 are currently pending in the application. Claim 1 is an independent claims. The following election of species remains in effect in the instant application: Cells to be separated: different cell lines; Medium conditions to modify: temperature; Solid support: polymer: polymethylacrylate; Stimulus-responsive polymer layer characteristics: temperature-responsive; Stimulus-response polymer layer components: homopolymers. Claims 17 and 20 remain withdrawn from consideration as being directed to a nonelected species, there being no allowable generic or linking claim. Claims 1-14, 16, 18-19, and 21 are currently pending and under examination in the instant application. An action on the merits follows. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Priority The present application is a 35 U.S.C. 371 national stage filing of International Application No. PCT/EP2020/055982, filed 06 March 2020, which claims priority to Germany 10 2019 106 011.7, filed 08 March 2019. Filing of a certified copy of the Germany 10 2019 106 011.7, filed 08 March 2019, is acknowledged. Thus, the earliest possible priority for the instant application is 08 March 2019. 37 CFR 1.121(c) The claim amendments filed 19 August 2026 is objected to under 37 CFR 1.121(c) because Applicant’s claim listing is not in compliance with 37 CFR 1.121(c) which states that the claim listing must provide the status of all claims, that all claims being currently amended in an amendment paper shall be presented in the claim listing, indicate a status of "currently amended," and be submitted with markings to indicate the changes that have been made relative to the immediate prior version of the claims. The text of any added subject matter must be shown by underlining the added text. The text of any deleted matter must be shown by strike-through except that double brackets placed before and after the deleted characters may be used to show deletion of five or fewer consecutive characters. The text of any deleted subject matter must be shown by being placed within double brackets if strike-through cannot be easily perceived. Specifically, claims 1, 8, 9, and 18 are marked “Currently amended” but lack any markings indicating insertions and deletions from the previous version. Additionally, amended claim 1 omits the deleted text “essentially” from line 8, “50%” from line 16, and “contained in the sample are separated” from line 16-17 of the prior version of the claim as filed 12 November 2025, which should be present and marked with a strikethrough and additionally does not underline inserted text “80%”, “isolated”, and “containing the at least two different types of cells” in lines 15-16 of the current claims set. Amended claims 8 and 18 each omits the deleted text “or” and fails to underline the inserted text “and”. Claim 9 omits the deleted text “pH-responsive PDEGMA layer,” and “, or a medium-responsive PDEGMA layer” as recited in lines 2-3 of the prior version of the claim as filed 12 November 2025. In the interests of compact prosecution, the claim listing has been entered. However, future claim listings must include the correct status of all claims, along with the appropriate mark-ups for changes to the claims, in order for the claim listing to meet the requirements for entry under 37 CFR 1.121(c) or a Notice of Non-Compliant Amendment will be mailed to applicant. Claim Objections *The following new objection is necessitated by amendments to the claims. Amended claim 9 is newly objected to because of the following informalities: amended claim 9 now recites, “aa” in line 2, which appears to be a typographical error for “a”. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The rejection of amended and previously presented claims 1-14, 16, and 18-19 under 35 U.S.C. 112(b) as failing to particularly point out and distinctly claim the subject matter which the inventor(s) regards as the invention for multiple issues of indefiniteness is withdrawn in view of Applicant’s amendments to the claims. Claim Rejections - 35 USC § 103 The rejection of amended and previously presented claims 1-14, 16, and 18-19 under 35 U.S.C. 103 as being unpatentable over Nagase et al. 2017, Acta Biomaterialia, 53, 81-92; in view of Yamato et al. 1999, Journal of Biomedical Materials Research, 44(1), 44-52; Fujimoto (US 8569048 B2), published 29 October 2013; and Anderson et al. 2017, Cellular and Molecular Bioengineering, 10(1), 75-88, published 24 August 2016, is withdrawn in view of Applicant’s claims which now recite wherein at least 80% of the at least one first type of cells are isolated from the sample containing the at least two different types of cells in amended independent claim 1. Claim Rejections - 35 USC § 112(a)- Scope of Enablement The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Amended, previously presented, and new claims 1-14, 16, 18-19, and 21 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for: A method for separating cells, comprising or consisting of: providing a sample containing at least two different types of cells; and contacting the sample with a cell culture substrate comprising a 5 nm thick thermoresponsive poly(di(ethylene glycol)methyl ether methacrylate) (PDEGMA) layer in a cell culture vessel; and subjecting the cell culture substrate and the at least two different types of cells to medium conditions at a temperature of about 37 oC which allows the at least two different types of cells to adhere to the cell culture substrate; and reducing the temperature to about 22 oC to decrease adherence of at least one first type of cells to the cell culture substrate, wherein the adherence of at least one second type of cells remains unaffected; and optionally flushing the cell culture substrate with a suitable cell culture medium or solvent to support the release of the at least one first type of cells with decreased adherence to the cell culture substrate; and agitating the cell culture vessel to support the release of the at least one first type of cells with decreased adherence to the cell culture substrate; and separating the at least one first type of cells released from the cell culture substrate from the at least one second type of cells that remain adhered to the cell culture substrate, wherein at least 80% of the at least one first type of cells are isolated from the sample containing the at least two different types of cells; and wherein the at least one first type of cells comprises PaTu 8988t cells and the at least one second type of cells comprises NIH3T3 cells; does not reasonably provide enablement for: A method for separating cells, comprising or consisting of: providing a sample containing any at least two different types of cells; and contacting the sample with a cell culture substrate comprising any stimulus-responsive poly(di(ethylene glycol)methyl ether methacrylate) (PDEGMA) layer in a cell culture vessel; and subjecting the cell culture substrate and the at least two different types of cells to any medium conditions which allow the at least two different types of cells to adhere to the cell culture substrate; and any modifying the medium conditions to decrease adherence of at least one first type of cells to the cell culture substrate, wherein the adherence of at least one second type of cells remains unaffected; and optionally flushing the cell culture substrate with a suitable cell culture medium or solvent to support the release of the at least one first type of cells with decreased adherence to the cell culture substrate; and agitating the cell culture vessel to support the release of the at least one first type of cells with decreased adherence to the cell culture substrate; and separating the at least one first type of cells released from the cell culture substrate from the at least one second type of cells that remain adhered to the cell culture substrate, wherein at least 80% of the at least one first type of cells are isolated from the sample containing the at least two different types of cells. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. This rejection comprises two (2) separate issues: 1) the absence of an enabling disclosure for separating cells using a cell culture substrate comprising any stimulus-responsive poly(di(ethylene glycol)methyl ether methacrylate) (PDEGMA) layer with any modifying the medium conditions to decrease adherence other than a 5 nm thick thermoresponsive PDEGMA layer wherein the modifying the medium conditions is reducing the culture temperature from about 37 oC to about 22 oC; and 2) the absence of an enabling disclosure for the separation of any at least two different types of cells from a sample other than PaTu 8988t cells from NIH3T3 cells. These issues were identified by the Office after analysis of the disclosure provided by the specification. The Office has analyzed the specification in direct accordance to the factors outlined in In re Wands, namely 1) the nature of the invention, 2) the state of the prior art, 3) the predictability of the art, 4) the amount of direction or guidance present, and 5) the presence or absence of working examples, and presented detailed scientific reasons supported by publications from the prior art for the finding of a lack of enablement for the scope of the instant methods. The Wands analysis and supporting specific evidence are presented below for each of the identified issues. As a first issue (1), the specification does not provide an enabling disclosure for separating cells using a cell culture substrate comprising any stimulus-responsive poly(di(ethylene glycol)methyl ether methacrylate) (PDEGMA) layer with any modifying the medium conditions to decrease adherence other than a 5 nm thick thermoresponsive PDEGMA layer wherein the modifying the medium conditions is reducing the culture temperature from about 37 oC to about 22 oC. The broadest independent claim, claim 1, recites a method for separating cells comprising or consisting of: providing a sample containing at least two different types of cells; contacting the sample with a cell culture substrate comprising a stimulus-responsive poly(di(ethylene glycol)methyl ether methacrylate) (PDEGMA) layer in a cell culture vessel; and subjecting the cell culture substrate and the at least two different types of cells to medium conditions which allow the at least two different types of cells to adhere to the cell culture substrate; and modifying the medium conditions to decrease adherence of at least one first type of cells to the cell culture substrate, wherein the adherence of at least one second type of cells remains unaffected; and optionally flushing the cell culture substrate with a suitable cell culture medium or solvent to support the release of the at least one first type of cells with decreased adherence to the cell culture substrate; and agitating the cell culture vessel to support the release of the at least one first type of cells with decreased adherence to the cell culture substrate; and separating the at least one first type of cells released from the cell culture substrate from the at least one second type of cells that remain adhered to the cell culture substrate, wherein at least 80% of the at least one first type of cells are isolated from the sample containing the at least two different types of cells. Claims 2-14, 16, 18-19, and 21 depend on claim 1. The specification generically discloses a stimulus-responsive polymer layer for cell separation [p 1 ¶ 2], wherein in various embodiments, the stimulus-responsive polymer layer is a pH-responsive polymer layer, a temperature-responsive polymer layer, a medium-responsive polymer layer, or may react to any suitable medium condition or stimulus [p 4 ¶ 5]. The specification further generically teaches wherein the stimulus-responsive polymer layer comprises or consists of at least one synthetic polymer that can undergo responsive behavior to external stimuli, e.g. temperature, pH, ionic strength, solvent, cell culture medium, salt, surfactant, and/or electric or magnetic field [p 13 ¶ 1]. The specification further generically teaches to change the particular stimulus corresponding to the stimulus to which the polymer is responsive, wherein the at least one cell type loses at least part of its adherence to the polymer layer due to the change in the conditions relative to the at least one other cells type [p 23 ¶ 1-4]. However, the specification does not teach any specific polymers having any specific stimulus-responsiveness other than PDEGMA polymers having thermoresponsiveness. The Examples of the specification teach separating cells from co-cultures only by using a thermoresponsive PDEGMA layer, wherein cells are adhered to the layer at about 37 oC, and wherein the temperature is reduced to about 22 oC to selectively release one type of cells from the co-culture [p 26-29]. Specifically, Example 1 teaches selective detachment of PaTu 8988t cells compared to NIH 3T3 cells co-cultured on a 5 nm thick PDEGMA layer at 37 oC for 24 hours followed by incubation at 22 oC for 30 minutes [p 27 ¶ 4, Figure 1]. Example 3 teaches adherence, releasing, and reseeding of PaTu 8988t and NIH 3T3 monocultures [p 28 ¶ 2, Figure 3]. Example 4 teaches attachment and release of PaTu 8988t and NIH 3T3 cocultures on a 5 nm thick PDEGMA layer, wherein PaTu 8988t cells are selectively released, without specifying the conditions for attachment nor for release [p 28 ¶ 3, Figure 4]. Example 5 teaches growth of induced pluripotent stem cells (iPSC) on a 5 nm thick PDEGMA layer at 37 oC followed by selective detachment of iPSCs from the heterogenous culture such that the differentiated cells remained on the PDEGMA layer at 22 oC [p 29 ¶ 1, Figure 5]. Example 6 presents detachment of iPSC colonies cultured on a 5 nm thick PDEGMA layer at 37 oC for 5 days and subsequently released at 22 oC [p 29 ¶ 2, Figure 6]. Example 8 teaches separation of iPSC colonies from surrounding differentiated cells cultured on a 5 nm thick PDEGMA layer at 37 oC for 5 days and subsequently released at 22 oC [p 29 ¶ 3, Figure 8]. The specification does not provide any examples of separating cells by changing any condition other than temperature, wherein the temperature change is a reduction from 37 oC to 22 oC. The art at the time of filing teaches that thermoresponsive polymers can be used for separating cells, such as a poly(N-isopropylacrylamide) (PIPAAm) thermoresponsive polymer for separating human dermal fibroblasts from human umbilical vein endothelial cells or for separating adipose-derived stem cells (ADSC) from other ADSC-related cells [Nagase et al. 2017, Acta Biomaterialia, 53, 81-92, cited in a prior action, abstract]. Additionally, Krishnamoorthy teaches that the chemistry of the repeat monomer unit is the key determinant of the environmental responsiveness [Krishnamoorthy et al. 2014, Chemical Reviews, 114, 10976-11026, p 10978 col 1 ¶ 2, Figure 1]. Krishnamoorthy teaches that systems sensitive to pH are based on polyacids and polybases and that temperature-sensitive brushes are based on polymers displaying an LCST or an upper critical solution temperature (UCST) in aqueous solutions [p 10978 col 1 ¶ 3m p 10978 col 2 ¶ 2]. Mendes teaches wherein specific chemical moieties are responsible for specific stimuli responsiveness, wherein control of surface properties is induced by diverse external stimulus such as chemical/biochemical, thermal, electric, and optical stimulus specific to the particular chemical functionalities of the chemical moieties within the polymers [Mendes 2008, Chemical Society Reviews, 37(11), 2361-2580, p 2513 col 2 ¶ 1, p 2515 col 1 ¶ 3, p 2516 col 2 ¶ 2-3, p 2517 col 2 ¶ 2, p 2518 col 1 ¶ 2, p 2519 col 1 ¶ 2, p 2521 col 1 ¶ 3, p 2524 col 1 ¶ 2, p 2525 col 1 ¶ 2, p 2525 col 2 ¶ 3, Figure 4, 5, 6, 7, 8, 9, 15, 16, 17]. For example, Mendes teaches that thermoresponsiveness arises from polymers that have a low critical solution temperature (LCST) such that below its LCST, the polymer is in an extended, solvent-swelled confirmation, but when heated up above the LCST, the polymer undergoes a phase transition to yield a collapsed morphology that excludes solvent, thereby breaking H-bonds between the polymer groups and water molecules so that the hydrophobic interactions become predominant, which promotes cell adhesion [p 2519 col 2 ¶ 2- p 2520 col 1 ¶ 1-2, Figure 9]. Mendes further teaches that the potential of switchable surfaces with dynamic properties for a wider range of application is promising, but that it will require concerted efforts from scientists in a variety of disciplines, including collaborative efforts of chemists, physicists, material scientists, engineers, medical researches, and biologists to fully explore the potential of switchable surfaces for biological and medical applications [p 2527 col 1 ¶ 2]. Porsch teaches that the LCST of PDEGMA is 27 oC, and that co-polymerization of PDEGMA with various ratios of OEGMA units results in various higher LCSTs [Porsch et al. 2011, Polymer Chemistry, 2, 1114-1123, Table 1]. Even as late as 2024, Giaouzi teaches that PDEGMA is a thermoresponsive polymer which requires co-polymerization with a pH-responsive polymer (PDMAEMA) to generate a copolymer with both thermoresponsive and pH-responsive behavior [Giaouzi & Pispas 2024, Polymer Chemistry, 15, 1536-1551, abstract, p 1537 col 1 ¶ 1-2]. Regarding the thermoresponsive polymer layer thickness, Kong teaches investigating films of the thermoresponsive polymer PNIPAAm with various thicknesses and various co-polymer ratios to assess the behaviors of cell adhesion and detachment [Kong et al. 2009, Biomaterials, 30, 5514-5522, abstract, p 5517 col 1 ¶ 1, Figure 3]. Kong further teaches wherein the optimal film thickness for PNIPAAm-grafted class surfaces to achieve the effective control of both cell adhesion and detachment is about 11-13 nm for NIH 3T3 fibroblast cells [abstract]. Kong teaches that NIH 3T3 cells adhered well at 3.3 nm or 4.4 nm thickness, but only partially detached when the temperature was reduced to 25 oC [p 5516 col 2 ¶ 3, Figure 3]. Conversely, NIH 3T3 cells only partially attached and did not proliferate well at 16.6 nm or 19.1 nm thickness [p 5517 col 1 ¶ 1- col 2 ¶ 1, Figure 3]. Kong teaches that their findings were consistent with the findings of another group which observed reversible adhesion and detachment of bovine endothelial cells on a 15.5 nm thick PNIPAAm film grafted onto tissue culture polystyrene, but no cell adhesion and proliferation were observed on the 29.3 nm thick film, such that adhesion of endothelial cells decreased and the film thickness increased [p 5517 col 2 ¶ 2]. Kong further notes the differences such that the fibroblasts used by Kong did not proliferate at a thickness above about 16 nm [p 5517 col 2 ¶ 2], suggesting potential cell-type specific effects contributing to the efficacy of attachment and proliferation. Kong goes on to teach that their results, along with prior reports, indicate that the control of cell adhesion and detachment is a complicated process determined interweavingly by many factors, such as substrate types, grafting methods, surface density of polymers, polymer thickness, and cell types [p 5517 col 2 ¶ 3]. Further, Voβ teaches that PDEGMA brushes with a dry ellipsometric thickness of 5 nm, which have transition temperatures of about 32 oC, can be switched from cell adherent behavior at 37 oC to cell nonadherent at 25 oC, as demonstrated for PaTu 8998T cells [Voβ et al. 2017, Macromolecular Bioscience, 17, 1600337, 1-12, abstract, p 11 col 1 ¶ 2, Figure 2]. Voβ also teaches that PDEGMA brushes with a dry ellipsometric thickness of greater than or equal to 10 nm did not allow PaTu 8988t cells to adhere at 37 oC, whereas 5 nm thin PDEGMA homopolymer brushes were shown to exhibit a temperature-induced transition from cell adherent behavior at 37 oC to cell nonadherent at 25 oC [p 11 col 1 ¶ 2]. Neither the specification nor the art at the time of filing teaches wherein PDEGMA can respond to any stimulus other than temperature to selectively adhere and/or release cells from a surface nor wherein any thickness of PDEGMA layer other than a 5 nm thick PDEGMA layer at 37 oC can adhere to and selectively release cells from the surface upon a stimulus change. Thus, in view of the art recognized correspondence between the chemical functionality of specific chemical moieties for facilitating specific stimulus responsiveness, such that individual moieties comprise individual stimulus-responsiveness; the teachings in the art the PDEGMA is a thermoresponsive polymer without pH-responsive functions; the teaching in the art that the LCST of PDEGMA is 27 oC or 35 oC, that temperatures above the LCST promote cell adhesion, and that temperatures above the LCST promote cell release; the art recognized criticality of the thickness of the thermoreversible polymer layer; the art recognized unpredictability in controlling cell adhesion and detachment which depends on many factors including substrate types, grafting methods, surface density of polymers, polymer thickness, and cell types; the limitation of the specification to teaching only 5 nm thick PDEGMA polymer layers for separation of cells by changing the temperature from adhesion at 37 oC to selective release at 22 oC; and the breadth of the claims; the ordinarily skilled artisan at the time of filing the instant application would have considered inducing a selective release of cells from any PDGEMA layer other than a 5 nm thick layer and by any means other than by reducing the temperature from about 37 oC to about 22 oC as highly unpredictable. As such, it would have required undue experimentation to practice the scope of Applicant’s invention as claimed. As a second issue (2), the specification does not provide an enabling disclosure for separating any at least two different types of cells other than PaTu 8988t cells from NIH3T3 cells or iPS cells from differentiated cells. The broadest independent claim, claim 1, recites a method for separating cells comprising or consisting of: providing a sample containing at least two different types of cells; contacting the sample with a cell culture substrate comprising a stimulus-responsive poly(di(ethylene glycol)methyl ether methacrylate) (PDEGMA) layer in a cell culture vessel; and subjecting the cell culture substrate and the at least two different types of cells to medium conditions which allow the at least two different types of cells to adhere to the cell culture substrate; and modifying the medium conditions to decrease adherence of at least one first type of cells to the cell culture substrate, wherein the adherence of at least one second type of cells remains unaffected; and optionally flushing the cell culture substrate with a suitable cell culture medium or solvent to support the release of the at least one first type of cells with decreased adherence to the cell culture substrate; and agitating the cell culture vessel to support the release of the at least one first type of cells with decreased adherence to the cell culture substrate; and separating the at least one first type of cells released from the cell culture substrate from the at least one second type of cells that remain adhered to the cell culture substrate, wherein at least 80% of the at least one first type of cells are isolated from the sample containing the at least two different types of cells. Claims 2-14, 16, 18-19, and 21 depend on claim 1. The specification generically discloses separation of cells wherein at least two different types of cells adhere to a substrate under given medium conditions with at least one type of cells being releasable by modification of said medium conditions [p 2 ¶ 5- p 3 ¶ 1]. The specification further generically teaches wherein the sample containing at least two different types of cells may result from cell experiments, may be from a natural source, and may be selected from a recited list of suitable cell types or cell mixtures [p 11 ¶ 2-6]. The specification also teaches generically wherein at least one first type of cells released from the cell culture substrate is separated from at least one second type of cells that remained adhered to the cell culture substrate [p 24 ¶ 5]. The Examples of the specification teach separating cells from co-cultures only by using a thermoresponsive PDEGMA layer, wherein cells are adhered to the layer at about 37 oC, and wherein the temperature is reduced to about 22 oC to selectively release one type of cells from the co-culture [p 26-29]. Specifically, Example 1 teaches selective detachment of PaTu 8988t cells compared to NIH 3T3 cells co-cultured on a PDEGMA layer at 37 oC for 24 hours followed by incubation at 22 oC for 30 minutes [p 27 ¶ 4, Figure 1]. Example 3 teaches adherence, releasing, and reseeding of PaTu 8988t and NIH 3T3 monocultures [p 28 ¶ 2, Figure 3]. Example 4 teaches attachment and release of PaTu 8988t and NIH 3T3 co-cultures on a PDEGMA layer, wherein PaTu 8988t cells are selectively released, without specifying the conditions for attachment nor for release [p 28 ¶ 3, Figure 4]. Example 5 teaches growth of induced pluripotent stem cells (iPSC) on a PDEGMA layer at 37 oC followed by selective detachment of iPSCs from the heterogenous culture such that the differentiated cells remained on the PDEGMA layer at 22 oC [p 29 ¶ 1, Figure 5]. Example 6 presents detachment of iPSC colonies cultured on a 5 nm thick PDEGMA layer at 37 oC for 5 days and subsequently released at 22 oC [p 29 ¶ 2, Figure 6]. Example 8 teaches separation of iPSC colonies from surrounding differentiated cells cultured on a 5 nm thick PDEGMA layer at 37 oC for 5 days and subsequently released at 22 oC [p 29 ¶ 3, Figure 8]. The specification does not provide any examples of separating cells other than a separation of PaTu 8988t cells from NIH 3T3 cells or a separation of iPSCs from differentiated cells. Further, the specification only teaches at least 80% cell of the at least one first type of cell isolated from the sample containing the at least two different type of cells for the co-culture of PaTu 8988t cells and NIH 3T3 cells. No quantitative recovery data is presented for the isolation of the iPS cells from the differentiated cells. Additionally, the specification does not teach any release temperatures or conditions for any other cell types. With respect to the second cell type wherein the adherence of at least one second type of cells remains unaffected, note that although the data presented in Figure 3d shows that the adherence difference for NIH 3T3 cells at 37 oC to 22 oC are statistically insignificant, the average adherence is slightly lower at 22 oC than at 37 oC on the PDEGMA surface. Additionally, Figure 4a indicates that some NIH 3T3 cells were released from the PDEGMA surface following a temperature reduction to 22 oC, which was greater than the number of cells released from TCPS at 22 oC as seen in Figure 4b. Accordingly, Applicant has not shown that the second cell type, NIH 3T3, remains entirely unaffected by the temperature change. The art at the time of filing teaches that thermoresponsive polymers can be used for separating or enriching cells, such as a poly(N-isopropylacrylamide) (PIPAAm) thermoresponsive polymer for separating human dermal fibroblasts from human umbilical vein endothelial cells or for separating adipose-derived stem cells (ADSC) from other ADSC-related cells [Nagase 2017, abstract]. Nagase further teaches that various cells types with different effective detachment temperatures from hydrophobic PIPAAm copolymer brushes were separated by multi-step temperature changes, with reference to Nagase (2013) [p 82 col 1 ¶ 1]. Nagase (2013) teaches the selective cell separation using thermoresponsive poly(N-isopropylacrylamide-co-butyl methacrylate) (P(IPAAm-co-BMA), including separation of human umbilical vein endothelial cells (HUVECs) and normal human dermal fibroblasts (NHDFs) based on their respective detachment temperatures of 20 and 10 oC, respectively [Nagase et al. 2013, Biomacromolecules, 14, 3423-3433, abstract, Figure 1, 9, 10]. Nagase (2013) further teaches that the results obtained from their investigations indicated that a precisely designed polymer brush was able to separate a mixture of cells by multistep temperature change, such that hydrophobized thermoresponsive copolymer brush surfaces would be applicable to cell separation by using cell temperature sensitivity for detachment [p 3431 col 2 ¶ 2]. Additionally, Krishnamoorthy teaches selective cell adhesion and manipulation through tailored brush composition [p 10996 col 2 ¶ 1, p 10997 col 1 ¶ 2- col 2 ¶ 1]. Krishnamoorthy teaches that PNIPAM has been used for controlled cell detachment with a wide range of cell types, including fibroblasts, epidermal cells, chondrocytes, aortic endothelial cells, muscle cells, kidney cells, cardiac myocytes, and hepatocytes [p 11000 col 2 ¶ 2], and that copolymers of PNIPAM which have found application for selective cell detachment [p 11000 col 2 ¶ 2]. As discussed above, Kong teaches that their results, along with prior reports, indicate that the control of cell adhesion and detachment is a complicated process determined interweavingly by many factors, such as substrate types, grafting methods, surface density of polymers, polymer thickness, and cell types [p 5517 col 2 ¶ 3]. Further, Voβ teaches that PDEGMA brushes with a dry ellipsometric thickness of 5 nm can be switched from cell adherent behavior at 37 oC to cell nonadherent at 25 oC, as demonstrated for PaTu 8998T cells [Voβ et al. 2017, Macromolecular Bioscience, 17, 1600337, 1-12, abstract, Figure 2]. Voβ also teaches that 83% of the PaTu 8988t cells detached from the PDEGMA surface following a reduction of temperature from about 37 oC to 25 oC [p 9 col 1 ¶ 3, Figure 6]. Braim teaches wherein each of NIH 3T3 cells and immortalized human MSCs can be adhered to a thermoresponsive PDEGMA layer at 37 oC and subsequently released from the thermoresponsive PDEGMA surface layer at 10 oC, but does not teach wherein adherence of the NIH 3T3 cells is unaffected at 22 oC compared to 37 oC [Braim et al. 2015, Journal of Materials Chemistry B, 4, 962-972, p 965 col 2 ¶ 8, p 966 col 1 ¶ 2]. Neither the specification nor the art at the time of filing teaches differential release of any individual cell types from any mixture of any two or more cell types from any thermoresponsive polymer surface. Neither the specification nor the art at the time of filing teaches expected adherence and release temperatures for the genus of cells encompassed by the instant claims for any thermoresponsive polymer layer; nor do the specification or the art at the time of filing teach a means to calculate or predict a release temperature for a cell type other than by empirical adhesion measurements involving testing each cell type with each thermoresponsive cell layer across temperatures. As such, at the time of filing, it would not have been predictable which cells would adhere at any given temperature, which cells would release at any given temperature, nor which cells would have different release temperatures, wherein one cell type releases at a particular temperature and another cell type remains unaffected at that temperature so as to allow differential release and thereby facilitate separation of the cell types. Thus, in view of the art recognized specificity of detachment temperatures for each cell type for each thermoresponsive polymer surface, such that separation of different cell types depends upon the cell types having different detachment temperatures; the limited variety of cell types which have been tested in the prior art for differential detachment under limited thermoresponsive polymer formulations; the art recognized unpredictability in controlling cell adhesion and detachment which depends on many factors including substrate types, grafting methods, surface density of polymers, polymer thickness, and cell types; the limitation in the specification to teaching separation of only two sets of cell types, wherein the specification teaches recovery of at least 80% of cells under culture modified conditions (i.e., at 22 oC) for only PaTu 8988t cells; and the breadth of the claims; the ordinarily skilled artisan at the time of filing the instant application would have considered inducing a selective release of any first type of cell from any second type of cell from a PDGEMA layer other than PaTu 8988t cells from NIH3T3 cells according to Applicant’s claimed method as highly unpredictable. As such, it would have required undue experimentation to practice the scope of Applicant’s invention as claimed. Conclusion No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. KATIE L PENNINGTON whose telephone number is (703)756-4622. The examiner can normally be reached M-Th 8:30 am - 5:30 pm, Friday 8:30 am - 12:30 pm CT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria G. Leavitt can be reached at (571) 272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. DR. KATIE L. PENNINGTON Examiner Art Unit 1634 /KATIE L PENNINGTON/Examiner, Art Unit 1634 Dr. A.M.S. Wehbé /ANNE MARIE S WEHBE/Primary Examiner, Art Unit 1634
Read full office action

Prosecution Timeline

Show 2 earlier events
May 22, 2025
Response Filed
Aug 14, 2025
Final Rejection mailed — §103, §112
Oct 14, 2025
Response after Non-Final Action
Nov 12, 2025
Request for Continued Examination
Nov 13, 2025
Response after Non-Final Action
Apr 22, 2026
Non-Final Rejection mailed — §103, §112
Aug 19, 2026
Response Filed
Oct 29, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735459
MODIFIED ADENO-ASSOCIATED VIRAL CAPSID PROTEINS FOR OCULAR GENE THERAPY AND METHODS OF USE THEREOF
5y 7m to grant Granted Sep 15, 2026
Patent 12714755
EFFECTIVE DOSAGES OF AN ADENOVIRAL-BASED BIOLOGICAL DELIVERY AND EXPRESSION SYSTEM FOR USE IN THE TREATMENT OF OSTEOARTHRITIS IN HUMANS, AND COMPOSITIONS COMPRISING THE SAME
4y 5m to grant Granted Aug 25, 2026
Patent 12703695
KU INHIBITORS AND THEIR USE
5y 0m to grant Granted Aug 11, 2026
Patent 12612644
SCALABLE METHOD FOR RECOMBINANT AAV PRODUCTION
5y 2m to grant Granted Apr 28, 2026
Patent 12583896
CAGED-DEGRON-BASED MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USING THE SAME
4y 9m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
32%
Grant Probability
93%
With Interview (+60.2%)
4y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 68 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month